JOINT FILING AGREEMENTJoint Filing Agreement • January 2nd, 2024 • MiCo IVD Holdings, LLC • In vitro & in vivo diagnostic substances
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Class ‘A’ Ordinary Shares, par value U.S.0.0109 per share, of Trinity Biotech plc, a company organized under the laws of Ireland. Each of them is responsible for the timely filing of such filings and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. This Joint Filing Agreement shall remain in full force and effect until revoked by any party hereto in a signed writing provided to each other party hereto, and then only with respect to such revoking
Price Return Swap AgreementPrice Return Swap Agreement • January 2nd, 2024 • MiCo IVD Holdings, LLC • In vitro & in vivo diagnostic substances
The Parties hereby enter into the Price Return Swap Agreement (hereinafter referred to as “this Agreement”) on December 20, 2023, as follows:
This Agreement shall be provided in accordance with applicable laws and regulations and internal control standards. Loan Agreement - Lender - Institutions specified in Appendix 1 - Borrower - Mainstream Holdings, Ltd. December 20, 2023Loan Agreement • January 2nd, 2024 • MiCo IVD Holdings, LLC • In vitro & in vivo diagnostic substances
This Loan Agreement [hereinafter referred to as “this Agreement”] is entered into on December 20, 2023 (the “Effective Date”), by the following parties.
